2019年ESMO亚洲大会：百济神州发表有关Tislelizumab的临床数据

2019-11-25 Allan MedSci原创

百济神州制药公司是一家商业阶段的生物制药公司，致力于开发和商业化用于治疗癌症的新型分子靶向和免疫肿瘤药物，近日宣布了来自II期临床的初步临床数据，该研究是抗PD-1抗体Tislelizumab联合化疗在胃/胃食管交界处（G / GEJ）腺癌或食道鳞状细胞癌（ESCC）患者中进行的试验。

百济神州制药公司是一家商业阶段的生物制药公司，致力于开发和商业化用于治疗癌症的新型分子靶向和免疫肿瘤药物，近日宣布了来自II期临床的初步临床数据，该研究是抗PD-1抗体Tislelizumab联合化疗在胃/胃食管交界处（G / GEJ）腺癌或食道鳞状细胞癌（ESCC）患者中进行的试验。

百济神州免疫肿瘤学首席医学官Yong Ben博士说：“在该试验中，Tislelizumab和化学疗法的联合治疗显示出持久的反应性，并且在G / GEJ腺癌或ESCC患者中普遍耐受良好。胃癌和食道癌是世界上最常见的癌症类型之一，代表了高度未满足的需求，尤其是在中国”。

原始出处：

http://www.firstwordpharma.com/node/1683108#axzz66FB9zUrI

本文系梅斯医学（MedSci）原创编译整理，转载需授权!

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言

评论区 (6)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=2024882, encodeId=a7662024882ac, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16459, encryptionId=c27516459de, topicName=SMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Mon Jan 20 12:46:00 CST 2020, time=2020-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016740, encodeId=a0a22016e4067, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22848, encryptionId=75a2228481a, topicName=临床数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Wed Jun 03 06:46:00 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912257, encodeId=cb25191225eaf, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Apr 16 23:46:00 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785810, encodeId=b0761e8581024, content=<a href='/topic/show?id=d028e02322' target=_blank style='color:#2F92EE;'>#ESMO亚洲大会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7023, encryptionId=d028e02322, topicName=ESMO亚洲大会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Mon Apr 27 09:46:00 CST 2020, time=2020-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281025, encodeId=761112810255b, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7021, encryptionId=50d6e0215a, topicName=ESMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Tue Nov 26 23:46:00 CST 2019, time=2019-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1345015, encodeId=8d51134501558, content=<a href='/topic/show?id=cf721640495' target=_blank style='color:#2F92EE;'>#SLE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16404, encryptionId=cf721640495, topicName=SLE)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kbRUeosenzlejlNGWXdWjSYhBKL1QYGQwfehJOkMXHiavh5wl7pKeju5Kcxdvr50ic6FWML3x6NMCxhG1bOaVjyA/132, createdBy=20872500216, createdName=ms4657536712156177, createdTime=Tue Nov 26 23:46:00 CST 2019, time=2019-11-26, status=1, ipAttribution=)]
2020-01-20 liuhuangbo

#SMO#

67 0
[GetPortalCommentsPageByObjectIdResponse(id=2024882, encodeId=a7662024882ac, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16459, encryptionId=c27516459de, topicName=SMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Mon Jan 20 12:46:00 CST 2020, time=2020-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016740, encodeId=a0a22016e4067, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22848, encryptionId=75a2228481a, topicName=临床数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Wed Jun 03 06:46:00 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912257, encodeId=cb25191225eaf, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Apr 16 23:46:00 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785810, encodeId=b0761e8581024, content=<a href='/topic/show?id=d028e02322' target=_blank style='color:#2F92EE;'>#ESMO亚洲大会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7023, encryptionId=d028e02322, topicName=ESMO亚洲大会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Mon Apr 27 09:46:00 CST 2020, time=2020-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281025, encodeId=761112810255b, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7021, encryptionId=50d6e0215a, topicName=ESMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Tue Nov 26 23:46:00 CST 2019, time=2019-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1345015, encodeId=8d51134501558, content=<a href='/topic/show?id=cf721640495' target=_blank style='color:#2F92EE;'>#SLE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16404, encryptionId=cf721640495, topicName=SLE)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kbRUeosenzlejlNGWXdWjSYhBKL1QYGQwfehJOkMXHiavh5wl7pKeju5Kcxdvr50ic6FWML3x6NMCxhG1bOaVjyA/132, createdBy=20872500216, createdName=ms4657536712156177, createdTime=Tue Nov 26 23:46:00 CST 2019, time=2019-11-26, status=1, ipAttribution=)]
2020-06-03 chenlianhui

#临床数据#

83 0
[GetPortalCommentsPageByObjectIdResponse(id=2024882, encodeId=a7662024882ac, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16459, encryptionId=c27516459de, topicName=SMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Mon Jan 20 12:46:00 CST 2020, time=2020-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016740, encodeId=a0a22016e4067, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22848, encryptionId=75a2228481a, topicName=临床数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Wed Jun 03 06:46:00 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912257, encodeId=cb25191225eaf, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Apr 16 23:46:00 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785810, encodeId=b0761e8581024, content=<a href='/topic/show?id=d028e02322' target=_blank style='color:#2F92EE;'>#ESMO亚洲大会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7023, encryptionId=d028e02322, topicName=ESMO亚洲大会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Mon Apr 27 09:46:00 CST 2020, time=2020-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281025, encodeId=761112810255b, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7021, encryptionId=50d6e0215a, topicName=ESMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Tue Nov 26 23:46:00 CST 2019, time=2019-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1345015, encodeId=8d51134501558, content=<a href='/topic/show?id=cf721640495' target=_blank style='color:#2F92EE;'>#SLE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16404, encryptionId=cf721640495, topicName=SLE)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kbRUeosenzlejlNGWXdWjSYhBKL1QYGQwfehJOkMXHiavh5wl7pKeju5Kcxdvr50ic6FWML3x6NMCxhG1bOaVjyA/132, createdBy=20872500216, createdName=ms4657536712156177, createdTime=Tue Nov 26 23:46:00 CST 2019, time=2019-11-26, status=1, ipAttribution=)]
2020-04-16 snf701207

#mAb#

61 0
[GetPortalCommentsPageByObjectIdResponse(id=2024882, encodeId=a7662024882ac, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16459, encryptionId=c27516459de, topicName=SMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Mon Jan 20 12:46:00 CST 2020, time=2020-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016740, encodeId=a0a22016e4067, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22848, encryptionId=75a2228481a, topicName=临床数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Wed Jun 03 06:46:00 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912257, encodeId=cb25191225eaf, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Apr 16 23:46:00 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785810, encodeId=b0761e8581024, content=<a href='/topic/show?id=d028e02322' target=_blank style='color:#2F92EE;'>#ESMO亚洲大会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7023, encryptionId=d028e02322, topicName=ESMO亚洲大会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Mon Apr 27 09:46:00 CST 2020, time=2020-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281025, encodeId=761112810255b, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7021, encryptionId=50d6e0215a, topicName=ESMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Tue Nov 26 23:46:00 CST 2019, time=2019-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1345015, encodeId=8d51134501558, content=<a href='/topic/show?id=cf721640495' target=_blank style='color:#2F92EE;'>#SLE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16404, encryptionId=cf721640495, topicName=SLE)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kbRUeosenzlejlNGWXdWjSYhBKL1QYGQwfehJOkMXHiavh5wl7pKeju5Kcxdvr50ic6FWML3x6NMCxhG1bOaVjyA/132, createdBy=20872500216, createdName=ms4657536712156177, createdTime=Tue Nov 26 23:46:00 CST 2019, time=2019-11-26, status=1, ipAttribution=)]
2020-04-27 klivis

#ESMO亚洲大会#

68 0
[GetPortalCommentsPageByObjectIdResponse(id=2024882, encodeId=a7662024882ac, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16459, encryptionId=c27516459de, topicName=SMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Mon Jan 20 12:46:00 CST 2020, time=2020-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016740, encodeId=a0a22016e4067, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22848, encryptionId=75a2228481a, topicName=临床数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Wed Jun 03 06:46:00 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912257, encodeId=cb25191225eaf, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Apr 16 23:46:00 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785810, encodeId=b0761e8581024, content=<a href='/topic/show?id=d028e02322' target=_blank style='color:#2F92EE;'>#ESMO亚洲大会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7023, encryptionId=d028e02322, topicName=ESMO亚洲大会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Mon Apr 27 09:46:00 CST 2020, time=2020-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281025, encodeId=761112810255b, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7021, encryptionId=50d6e0215a, topicName=ESMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Tue Nov 26 23:46:00 CST 2019, time=2019-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1345015, encodeId=8d51134501558, content=<a href='/topic/show?id=cf721640495' target=_blank style='color:#2F92EE;'>#SLE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16404, encryptionId=cf721640495, topicName=SLE)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kbRUeosenzlejlNGWXdWjSYhBKL1QYGQwfehJOkMXHiavh5wl7pKeju5Kcxdvr50ic6FWML3x6NMCxhG1bOaVjyA/132, createdBy=20872500216, createdName=ms4657536712156177, createdTime=Tue Nov 26 23:46:00 CST 2019, time=2019-11-26, status=1, ipAttribution=)]
2019-11-26 zhang92560

#ESMO#

68 0
[GetPortalCommentsPageByObjectIdResponse(id=2024882, encodeId=a7662024882ac, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16459, encryptionId=c27516459de, topicName=SMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Mon Jan 20 12:46:00 CST 2020, time=2020-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016740, encodeId=a0a22016e4067, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22848, encryptionId=75a2228481a, topicName=临床数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Wed Jun 03 06:46:00 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912257, encodeId=cb25191225eaf, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Apr 16 23:46:00 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785810, encodeId=b0761e8581024, content=<a href='/topic/show?id=d028e02322' target=_blank style='color:#2F92EE;'>#ESMO亚洲大会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7023, encryptionId=d028e02322, topicName=ESMO亚洲大会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Mon Apr 27 09:46:00 CST 2020, time=2020-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281025, encodeId=761112810255b, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7021, encryptionId=50d6e0215a, topicName=ESMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Tue Nov 26 23:46:00 CST 2019, time=2019-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1345015, encodeId=8d51134501558, content=<a href='/topic/show?id=cf721640495' target=_blank style='color:#2F92EE;'>#SLE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16404, encryptionId=cf721640495, topicName=SLE)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kbRUeosenzlejlNGWXdWjSYhBKL1QYGQwfehJOkMXHiavh5wl7pKeju5Kcxdvr50ic6FWML3x6NMCxhG1bOaVjyA/132, createdBy=20872500216, createdName=ms4657536712156177, createdTime=Tue Nov 26 23:46:00 CST 2019, time=2019-11-26, status=1, ipAttribution=)]
2019-11-26 ms4657536712156177

#SLE#

57 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

消化

2019年ESMO亚洲大会：百济神州发表有关Tislelizumab的临床数据

相关资讯

科室

工具

服务